Match!

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

Published on May 1, 2019in Nature Medicine30.64
· DOI :10.1038/s41591-019-0424-4
Jordi Rodon37
Estimated H-index: 37
(University of Texas MD Anderson Cancer Center),
Jean-Charles Soria69
Estimated H-index: 69
+ 22 AuthorsRazelle Kurzrock95
Estimated H-index: 95
(UCSD: University of California, San Diego)
Abstract
Precision medicine focuses on DNA abnormalities, but not all tumors have tractable genomic alterations. The WINTHER trial ( NCT01856296 ) navigated patients to therapy on the basis of fresh biopsy-derived DNA sequencing (arm A; 236 gene panel) or RNA expression (arm B; comparing tumor to normal). The clinical management committee (investigators from five countries) recommended therapies, prioritizing genomic matches; physicians determined the therapy given. Matching scores were calculated post-hoc for each patient, according to drugs received: for DNA, the number of alterations matched divided by the total alteration number; for RNA, expression-matched drug ranks. Overall, 303 patients consented; 107 (35%; 69 in arm A and 38 in arm B) were evaluable for therapy. The median number of previous therapies was three. The most common diagnoses were colon, head and neck, and lung cancers. Among the 107 patients, the rate of stable disease ≥6 months and partial or complete response was 26.2% (arm A: 23.2%; arm B: 31.6% (P = 0.37)). The patient proportion with WINTHER versus previous therapy progression-free survival ratio of >1.5 was 22.4%, which did not meet the pre-specified primary end point. Fewer previous therapies, better performance status and higher matching score correlated with longer progression-free survival (all P < 0.05, multivariate). Our study shows that genomic and transcriptomic profiling are both useful for improving therapy recommendations and patient outcome, and expands personalized cancer treatment.
  • References (39)
  • Citations (3)
References39
Newest
#1Cheyennedra C. Bieg-Bourne (UCSD: University of California, San Diego)H-Index: 1
#2Sherri Z. Millis (Foundation Medicine)H-Index: 10
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 95
view all 8 authors...
#1Aaron Goodman (UCSD: University of California, San Diego)H-Index: 8
#2Shumei Kato (UCSD: University of California, San Diego)H-Index: 11
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 95
view all 9 authors...
#1Shumei Kato (UCSD: University of California, San Diego)H-Index: 11
#2Nithya Krishnamurthy (UCSD: University of California, San Diego)H-Index: 3
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 95
view all 10 authors...
#1Dung T. Le (Johns Hopkins University)H-Index: 30
#2Jennifer N. Durham (Johns Hopkins University)H-Index: 3
Last.Brandon Luber (Johns Hopkins University)H-Index: 18
view all 46 authors...
#1Christophe Massard (Université Paris-Saclay)H-Index: 41
#2Stefan Michiels (Université Paris-Saclay)H-Index: 48
Last.Jean-Charles Soria (Université Paris-Saclay)H-Index: 32
view all 33 authors...
#1Apostolia Maria Tsimberidou (University of Texas MD Anderson Cancer Center)H-Index: 49
#2David K. Hong (University of Texas MD Anderson Cancer Center)H-Index: 52
Last.Filip Janku (University of Texas MD Anderson Cancer Center)H-Index: 38
view all 18 authors...
#1Maria Schwaederle (UCSD: University of California, San Diego)H-Index: 18
#2Melissa Zhao (UCSD: University of California, San Diego)H-Index: 2
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 95
view all 8 authors...
#1Maria Schwaederle (UCSD: University of California, San Diego)H-Index: 18
#2Barbara A. Parker (UCSD: University of California, San Diego)H-Index: 50
Last.Paul T. Fanta (UCSD: University of California, San Diego)H-Index: 15
view all 12 authors...
Cited By3
Newest
#1Elena Poddubskaya (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 5
Last.Alexey Moisseev (MSMU: I.M. Sechenov First Moscow State Medical University)
view all 0 authors...
#1Johannes Doescher (University of Ulm)H-Index: 5
#2Stephanie E Weissinger (University of Ulm)H-Index: 6
Last.Thomas K. Hoffmann (University of Ulm)H-Index: 38
view all 13 authors...
#1Rakesh Kumar (Rajiv Gandhi Centre for Biotechnology)
#2M. van VlietH-Index: 67
Last.Larry Norton (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 95
view all 7 authors...
#1Anton Buzdin (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 1
#2Maxim Sorokin (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 6
Last.Alf GieseH-Index: 26
view all 0 authors...
View next paperCopenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials